title: Therapeutic approaches for ischemia/reperfusion injury in the liver.
abstract: Organ injury caused by transient ischemia followed by reperfusion is associated with a number of clinically and environmentally induced conditions. Ischemia/reperfusion (I/R) conditions arise during surgical interventions such as organ transplantation and coronary bypass surgery, and in diseases such as stroke and cardiac infarct. The destructive effects of I/R arise from the acute generation of reactive oxygen species subsequent to reoxygenation, which inflict direct tissue damage and initiate a cascade of deleterious cellular responses leading to inflammation, cell death, and organ failure. This review summarizes existing and potential approaches for treatment that have been developed from research using model systems of I/R injury. Although I/R injury in the liver is emphasized, other organ systems share similar pathophysiological mechanisms and therapeutic approaches. We also review current knowledge of the molecular events controlling cellular responses to I/R injury, such as activation of AP-1 and NF-kappaB pathways. Therapeutic strategies aimed at ameliorating I/R damage are focused both on controlling ROS generated at the time of oxygen reperfusion and on intervening in the activated signal transduction cascades. Potential therapies include pharmacological treatment with small molecules, antibodies to cytokines, or free-radical scavenging enzymes, such as superoxide dismutase or catalase. Additionally, the use of gene therapy approaches may significantly contribute to the development of strategies aimed at inhibiting of I/R injury.
authors.affiliation: Molecular Biology Program, College of Medicine, University of Iowa, Iowa City 52242, USA.
authors.forename: C
authors.initials: C
authors.lastname: Fan
authors.forename: R M
authors.initials: RM
authors.lastname: Zwacka
authors.forename: J F
authors.initials: JF
authors.lastname: Engelhardt
mesh_terms: D000818:Animals; D016166:Free Radical Scavengers / Q000627:therapeutic use; D015316:Genetic Therapy; D006360:Heat-Shock Proteins / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000098:blood supply* / Q000187:drug effects / Q000378:metabolism*; D016328:NF-kappa B / Q000378:metabolism; D009569:Nitric Oxide / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D015427:Reperfusion Injury / Q000378:metabolism / Q000628:therapy*; D015398:Signal Transduction / Q000235:genetics; D018808:Transcription Factor AP-1 / Q000378:metabolism
chemical_list: D016166:Free Radical Scavengers; D006360:Heat-Shock Proteins; D016328:NF-kappa B; D017382:Reactive Oxygen Species; D018808:Transcription Factor AP-1; D009569:Nitric Oxide